Opportunity Information: Apply for RFA MH 23 260
Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional) is a National Institute of Mental Health (NIMH), National Institutes of Health (NIH) funding opportunity (RFA-MH-23-260) that supports research aimed at reducing suicide risk and strengthening resilience in low- and middle-income countries (LMICs). The focus is on evaluating multilevel prevention strategies that address suicide ideation and behaviors, including self-harm and suicide attempts, across different age groups and life stages. The opportunity is built around the idea that suicide prevention in LMICs requires approaches that fit local cultures, systems, and resources, rather than simply importing interventions designed for high-income settings.
The core purpose of the grant is to fund both experimental and non-experimental studies that test or assess preventive strategies operating at more than one level. This includes individual-level approaches often described as selective prevention (targeting people or groups at elevated risk) as well as population-level or universal prevention strategies (aimed at broader communities or entire populations). NIMH is emphasizing that effective prevention in LMICs will likely require combining or coordinating interventions across settings such as health care, schools, workplaces, families, and community systems, while accounting for multiple risk factors (for example, mental health conditions, substance use, trauma exposure, social stressors) and protective factors (such as connectedness, supportive relationships, coping skills, access to care, and community-level supports).
As an R34 mechanism, the award is generally positioned as a grant type that supports early-stage or preparatory clinical research, including feasibility, pilot testing, refinement of approaches, and building the evidence base needed for larger trials or broader implementation. The listing notes "Clinical Trial Optional," meaning applicants may propose a study that includes a clinical trial component, but they are not required to do so; proposals can be designed either with or without a clinical trial depending on the research question and stage of intervention development.
In terms of funding details, the opportunity is categorized as a discretionary grant in the health area (CFDA 93.242). The award ceiling is listed as $450,000, indicating the maximum anticipated funding level per award under this announcement. The original closing date was June 20, 2023, and the announcement was created on March 28, 2023. While the expected number of awards is not specified in the provided text, the ceiling and mechanism suggest a competitive, targeted call focused on generating actionable evidence for suicide prevention strategies that can work in LMIC contexts.
Eligibility is broad and includes many types of U.S.-based and non-U.S. organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and other Native American tribal organizations. It also includes public housing authorities/Indian housing authorities, nonprofit organizations (both with and without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses. The announcement explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, Indian/Native American Tribal Governments that are not federally recognized, and non-domestic (non-U.S.) entities, including foreign organizations. This wide eligibility aligns with the global scope of the work and the expectation that successful projects may require partnerships among academic institutions, community organizations, health systems, and government stakeholders in LMIC settings.
Overall, this opportunity is geared toward building practical, culturally responsive evidence on how to prevent suicide and promote resilience across the lifespan in LMICs by testing prevention strategies that operate at multiple levels, from targeted supports for high-risk groups to broader community or population-level approaches.Apply for RFA MH 23 260
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2023-03-28.
- Applicants must submit their applications by 2023-06-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional) - RFA-MH-23-260
What is this funding opportunity?
This is a National Institute of Mental Health (NIMH), National Institutes of Health (NIH) funding opportunity titled "Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional)." The funding opportunity announcement (FOA) number is RFA-MH-23-260.
What is the main goal of the grant?
The main goal is to support research that reduces suicide risk and strengthens resilience in low- and middle-income countries (LMICs). The emphasis is on evaluating prevention strategies that address suicide ideation and behaviors, including self-harm and suicide attempts, across different age groups and life stages.
Why is the focus specifically on LMICs?
The opportunity is built on the premise that suicide prevention in LMICs often requires approaches tailored to local cultures, systems, and available resources, rather than simply importing interventions designed for high-income settings.
What kinds of studies does the FOA support?
The FOA supports both experimental and non-experimental studies that test or assess preventive strategies operating at more than one level (multilevel approaches).
What does "multilevel prevention strategies" mean in this context?
Multilevel strategies are approaches that operate across more than one level of influence. Based on the FOA description, this can include combining or coordinating interventions across settings such as health care, schools, workplaces, families, and community systems, rather than focusing only on one setting or one type of intervention.
Does the FOA allow projects that focus on high-risk groups?
Yes. The FOA explicitly includes individual-level approaches often described as selective prevention, meaning interventions that target people or groups at elevated risk.
Does the FOA allow population-wide or community-wide prevention approaches?
Yes. The FOA also includes population-level or universal prevention strategies aimed at broader communities or entire populations.
Is it expected that projects combine selective and universal approaches?
The FOA emphasizes that effective prevention in LMICs will likely require combining or coordinating interventions across different settings and levels, which can include both selective and universal components, depending on the proposed strategy.
What suicide-related outcomes are within scope?
The scope includes suicide ideation and behaviors, including self-harm and suicide attempts.
Does the FOA specify risk factors and protective factors that projects can address?
Yes. The FOA description references multiple risk factors such as mental health conditions, substance use, trauma exposure, and social stressors, as well as protective factors such as connectedness, supportive relationships, coping skills, access to care, and community-level supports.
What does the R34 mechanism mean for applicants?
As an R34 mechanism, the award is generally positioned to support early-stage or preparatory clinical research. This can include feasibility studies, pilot testing, refinement of approaches, and building the evidence base needed for larger trials or broader implementation.
What does "Clinical Trial Optional" mean?
"Clinical Trial Optional" means applicants may propose a study that includes a clinical trial component, but they are not required to do so. Proposals may be designed with or without a clinical trial depending on the research question and the stage of intervention development.
Which agency is offering this grant?
The grant is offered by the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What is the assistance listing / CFDA number and program area?
The opportunity is listed under CFDA (Assistance Listing) 93.242 and is categorized in the health area as a discretionary grant.
What is the maximum award amount?
The award ceiling is listed as $450,000, which indicates the maximum anticipated funding level per award under this announcement.
How many awards will be made?
The expected number of awards is not specified in the information provided.
What were the key dates for this FOA?
The announcement was created on March 28, 2023. The original closing date was June 20, 2023.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based and non-U.S. organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and other Native American tribal organizations. It also includes public housing authorities/Indian housing authorities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.
Are non-U.S. organizations allowed to apply?
Yes. The announcement includes non-domestic (non-U.S.) entities, including foreign organizations, as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among the eligible applicants described.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly highlighted as eligible applicants.
Are minority-serving institutions included as eligible applicants?
Yes. The announcement highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are tribal entities eligible even if they are not federally recognized?
Yes. The eligibility list includes Indian/Native American Tribal Governments that are not federally recognized.
Can federal agencies apply?
Yes. Eligible federal agencies are explicitly included among eligible applicants.
What types of partnerships or collaborations fit this FOA?
The FOA description indicates that successful projects may require partnerships among academic institutions, community organizations, health systems, and government stakeholders in LMIC settings, consistent with the multilevel and culturally responsive focus.
Is the FOA oriented toward implementation of established programs from high-income countries?
The FOA emphasizes that approaches should fit local cultures, systems, and resources in LMICs, rather than simply importing interventions designed for high-income settings.
Is the focus limited to a single age group?
No. The FOA focuses on suicide prevention across the life span, covering different age groups and life stages.
What is the overall emphasis of the opportunity?
The overall emphasis is on generating practical, culturally responsive evidence for preventing suicide and promoting resilience in LMICs by evaluating prevention strategies that operate at multiple levels, from targeted supports for higher-risk groups to broader community or population-level approaches.
Browse more opportunities from the same category: Health
Next opportunity: Tobacco Regulatory Science (R01 Clinical Trial Optional)
Previous opportunity: NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 23 260
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 23 260) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIH Directors Early Independence Awards (DP5 Clinical Trial Optional) Apply for RFA RM 23 007 Funding Number: RFA RM 23 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional) Apply for RFA NS 23 021 Funding Number: RFA NS 23 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) Apply for RFA RM 23 005 Funding Number: RFA RM 23 005 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed) Apply for PAR 23 132 Funding Number: PAR 23 132 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 022 Funding Number: RFA AI 23 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed) Apply for PAR 23 133 Funding Number: PAR 23 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional) Apply for RFA NS 23 022 Funding Number: RFA NS 23 022 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) Apply for PAR 23 148 Funding Number: PAR 23 148 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Developing Measures to Advance Access and Quality in Global Mental Health Services (R34 Clinical Trial Not Allowed) Apply for RFA MH 23 300 Funding Number: RFA MH 23 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing and Evaluating New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID (U18) Apply for RFA HS 23 012 Funding Number: RFA HS 23 012 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional) Apply for RFA NS 24 022 Funding Number: RFA NS 24 022 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional) Apply for PAR 23 141 Funding Number: PAR 23 141 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 23 162 Funding Number: PAR 23 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed) Apply for RFA AR 24 003 Funding Number: RFA AR 24 003 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Developing Measures to Advance Quality in Mental Health Care Services (R01 Clinical Trial Not Allowed) Apply for RFA MH 23 265 Funding Number: RFA MH 23 265 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fundamental Research to Understand the Mechanisms of Neurotropic Virus-mediated Disease (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 028 Funding Number: RFA AI 23 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R21 Clinical Trial Not Allowed) Apply for RFA DE 24 002 Funding Number: RFA DE 24 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 23 165 Funding Number: PAR 23 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Apply for PAR 23 164 Funding Number: PAR 23 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for PAR 23 154 Funding Number: PAR 23 154 Agency: National Institutes of Health Category: Health Funding Amount: $360,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 23 260", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.